Annals of the Rheumatic Diseases

Annals of the Rheumatic Diseases (#1 research journal in Rheumatology). High quality, peer reviewed research.

[Annals of the Rheumatic Diseases @eular_ARD]

🦋 #EULAR2026: New Insights into #SLE Therapy
(Bertsias)

Withdraw GC first in sustained remission; consider IS/biologic withdrawal after ≥3 yrs.
Safest GC withdrawal when 3 factors combine: slow taper (6m) + good HCQ adherence + remission (DORIS/LLDAS)

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2026: Treating PH in CTD (Allanore)

Novel disease-modifying drug → sotatercept (TGF-β/activin pathway), can reverse pulmonary vascular remodeling.
Unlike idiopathic #PAH, CTD-PAH has an autoimmune component → treat the disease + the pulmonary vasculature.

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

Periostin-expressing fibroblasts: another kid on the blicknof RA synovium and PsA skin involvement?

Wonderful presentation by @carolineospelt

#EULAR2026 @javierrcarrio

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2026 debate: To (Re)biopsy or Not in ANCA-Associated Vasculitis?

⚖️ Jayne (Pro): biopsy stays guideline-recommended: diagnosis, prognosis & drug selection
⚖️ Tomelleri (Contra): renal biopsy may be replaced by biomarkers (usCD163, uMCP-1, uEGF) and imaging

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

Platelets as leading drivers of immune processes in autoimmunity @m_scherlinger
➡️ fuel inflammation
➡️promote organ damage
➡️potential therapeutic target

Very interesting and well attended session! @javierrcarrio

[Annals of the Rheumatic Diseases @eular_ARD]

🧬 #EULAR2026 Systemic Sclerosis, by Oliver Distler
Cell-based & T-cell engaging therapies enter refractory SSc:
🔹 CAR-T: median pFVC +6.4% at 6m (BREAKFREE-1)
🔹 BCMA-TCE teclistamab: ↓mRSS & tendon friction rubs (Nat Med 2026)
Beyond conventional IS.
#SSc

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2026: GCA & Takayasu, Shared Pathways, Different Ages?
Two prototypes, one spectrum.
TAK: CD8+ cytotoxic injury, prominent fibrosis
GCA: macrophage-driven, self-renewing lesions
Shared IL-6/JAK response; TNFi only in TAK

from Weyand, Tomelleri, Direskeneli

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2026 Prof. Della Torre

When to suspect #IgG4RD: tumefactive/stenosing lesions AFTER excluding malignancies & infections.
Serum IgG4 are NOT diagnostic: interpret in context. FDG-PET helps map disease burden. Histology remains the mainstay.

@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

Loreto Carmona @Inmusc1 guide us through the implementation strategy

Very practical tips from @eular_org recommendations and #educAr initiative

CFIR-ERIC marching tool and StrategEase tool provide valuable tools

@javierrcarrio

[Annals of the Rheumatic Diseases @eular_ARD]

Which implementation model should I choose?
➡️Dr. Schiphof introduces the whole implementation process and decision-making.
➡️Useful examples from @eular_org OA recommendations
➡️ Combination is optimal

@javierrcarrio

[Annals of the Rheumatic Diseases @eular_ARD]

#HOTsession #EULAR2026: Treatment of ICI-induced rheumatic #irAEs by Prof Koops
Key points:
✅ From mild to life-threatening
✅ Treat early, don't await the full diagnostic picture
✅ Control symptoms while supporting cancer therapy
✅ Collaboration with oncologist
@ElvisHysa

[Annals of the Rheumatic Diseases @eular_ARD]

Some of the faces behind the posts! Regular and guest social media editors of @eular_ARD and @eular_ero catching up at #EULAR2026
@epirheum @RafaPrieto4 @ElvisHysa @dr_emrebilgin @Nellziade @RubenDFernandes @Ertugrul_cagri @daliyapencheva @javierrcarrio @alessia_alunno

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2026 congress is starting tomorrow and we are thrilled to introduce this year’s guest social media editors. Make sure you follow also ARD sister journal @eular_ero for live updates! #rheumedu

[Annals of the Rheumatic Diseases @eular_ARD]

EULAR highlights🔵

➡️long-term follow up data from the ARIAA study: 6months treatment intervention w Abatacept delays progression to RA for up to 4 years in ACPA+ patients w artralgia!

#EULA25
@BurjaBlaz

[Annals of the Rheumatic Diseases @eular_ARD]

👋🏼We say goodbye to the #EULAR2025 Congress with the Highlights session, summarising all the amazing work of this edition.

⏭️ Looking forward to seeing you in London for the #EULAR2026.

@RafaPrieto4

[Annals of the Rheumatic Diseases @eular_ARD]

Great session yesterday on #DISH with a talk from @Nellziade. Even Ramses might have had it! It was very insightful also to learn about the role of comirbidities, especially #diabetes! #EULAR2025

Posted by @msokolova_rheum

[Annals of the Rheumatic Diseases @eular_ARD]

💉Digital ulcers in SSc

➡️selexipag (prostacyclin receptor agonist) showed superior results in treating DU in SSc as compared to iloprost
➡️off-label use in retrospective multicentre italian study
➡️further trials needed to confirm promising results

#EULAR2025
@BurjaBlaz

[Annals of the Rheumatic Diseases @eular_ARD]

A rarely discussed topic of #rheumatoid vasculitis - a great talk from Dr. Makol from the @MayoClinic at #EULAR2025
⭐️still very high mortality!
⭐️suspect in smn with constitutional symptoms, low complement (C3!) and ⬆️APR
⭐️RTX emerging as a treatment option
By @msokolova_rheum

[Annals of the Rheumatic Diseases @eular_ARD]

❓How to improve adherence during the transition from paediatric to adult care?
🔝A great session including in the same session the voice of patients, HPRs and rheumatologists, supported by @FerEstevezLopez and Loreto Carmona as chairs.

#EULAR2025
@RafaPrieto4

[Annals of the Rheumatic Diseases @eular_ARD]

#EULAR2025 WIN in large vessel vasculitis.
⚠️up to 30% #PMR patients have subclinical #GCA which is associated with:
⚠️older age
⬆️ morning stiffness
⬆️hip involvement
If you start with ⬇️ than 20 mg pred in subclin. GCA-> 100% relapse risk!
Posted by @msokolova_rheum